Introduction
The proto-oncogene c-kit was first identified as the oncogenic component of the acutely transforming Hardy-Zuckerman 4-feline sarcoma virus 1 . It encodes Kit, a type III receptor tyrosine kinase that binds the ligand stem cell factor (SCF) 2 . Structurally, Kit is related to the receptors for platelet derived growth factor, vascular endothelial growth factor, fibroblast growth factor, and FLT-3 ligand (reviewed in 3 ). All contain an extracellular ligand-binding domain In both people and dogs, malignant mast cell disease often warrants an extremely poor prognosis. To date, no reliable effective chemotherapeutic agents have been identified 25,30-34 . More recently, systemic mast cell disorders in people have been treated with interferon-α, although the effectiveness of this therapy has been variable [35] [36] [37] [38] [39] [40] [41] [42] [43] . Recent studies suggest that tumors expressing activating mutations in Kit may be amenable to treatment with Kit inhibitors. This has been particularly relevant for gastrointestinal stromal tumors (GISTs), most of which possess deletions of various size in exon 11 of c-kit that lead to autophosphorylation of Kit in the absence of ligand binding 44-48 . These tumors respond poorly to conventional chemotherapeutics but exhibit a significant susceptibility (in preliminary trials) to treatment with the tyrosine kinase inhibitor imatinib mesylate (STI571, Gleevec®) 49-51 .
The purpose of the following study was to identify an RTK inhibitor capable of blocking the function of multiple forms of mutant Kit. This is of particular importance in light of the fact that STI571 does not appear to be an effective inhibitor of the catalytic domain Kit mutant (most commonly found in human mastocytosis), and that resistance to STI571 has been noted in treated patients, making the development and application of additional inhibitors necessary 52-57 .
The earliest small molecule with an indolinone chemical structure to enter clinical testing (SU5416; semaxanib) was targeted to inhibit a single RTK, VEGFR-2, based on the hypothesis that broadly targeting multiple RTKs might result in unexpected toxicities. Later, clinical experience with a second indolinone (SU6668) with inhibitory activity against the family of RTKs with split kinase domains (VEGFR-2, FGF-R, and PDGF-R, all thought to materially contribute to the process of neovascularization) showed these concerns to be unwarranted 58 .
The newest series of indolinones, SU11652, SU11654 and SU11655, were also designed to inhibit VEGF-R, PDGF-R, FGF-R, and Kit family members. These indolinone-based compounds all act as competitive inhibitors with respect to ATP for binding to the intracellular catalytic domain. For comparison, potency (as measured by IC 50 for biochemical and cellular inhibition of phosphorylation of these receptors) are shown in Table 1 59-61 .
We therefore undertook a series of experiments to determine the potency of these compounds in functional inhibition of a variety of cell lines expressing mutant Kit, using phosphorylation of the receptor, cell viability, and apoptosis as read-outs for activity. Our studies demonstrate that all three indolinones are capable of inhibiting autophosphorylation of 
Materials and Methods

Cell culture
The BR canine mastocytoma cell line (possessing a point mutation in the juxtamembrane domain, Leu575Pro) and the C2 canine mastocytoma cell line (possessing a 48 bp tandem duplication in the juxtamembrane domain) were generously provided by Dr. Warren Gold (Cardiovascular Research Institute, UCSF). The P815 mouse mastocytoma cell line (possessing a point mutation in the catalytic domain, Asp814Tyr) was purchased from American Type Culture Collection (Manassas, VA). The C57 mouse mast cell line (expressing wild-type Kit) was generously provided by Dr. Stephen Galli (Department of Pathology, Stanford University). All cell lines were maintained in RPMI 1640 supplemented with 10% Fetal bovine serum, nonessential amino acids, sodium pyruvate, HEPES, penicillin, streptomycin and L-glutamine.
Indolinone Reagents
The 
Cell Viability/Proliferation
The BR, C2 and P815 cells were counted then resuspended in 24 well plates at a concentration of 0.5×10 6 For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From addition of the loading buffer. SDS-PAGE was performed using 7.5% or 10% gels, samples were transferred to PVDF membrane, and the membranes were incubated with either anti-PI 3-kinase, anti-SHP-1, or anti phosphotyrosine antibodies. Membranes were developed using SuperSignal ECL (Pierce, Rockford, IL), then stripped using a buffer consisting of 2%w/v SDS, 62.5mM Tris HCl pH6.8, 100mM β-Mercaptoethanol for 1min at 50º. Membranes were then reprobed for Kit using the Ab-1 anti-Kit antibody. The effect of various Kit mutations on downstream signaling events that regulate cell growth and function is not completely characterized. However, it is now known that activation of PI 3-kinase by Kit is important for malignant transformation 67,68 . As previously reported,
Kit autophosphorylation was present in the absence of SCF stimulation in the cell lines possessing mutations in the catalytic or JM domains. Additionally, we found that PI 3-kinase was constitutively associated with mutant Kit in the presence of mutation in either the juxtamembrane or catalytic domain, but as expected, not in the presence of WT Kit (Fig. 1c) .
Interestingly, the point mutation in the JM domain led to slightly less autophosphorylation of Kit than the other two mutants, as well as a lower level of PI 3-kinase association, suggesting that point mutations in the JM domain may be less likely to result in transforming events.
The tyrosine phosphatase SHP-1 is known to bind to Kit in the JM domain and is believed to negatively regulate receptor function. We initially believed that mutations in the JM Moreover, a recent study identified critical residues in the Kit intracellular JM domain that exist in a putative α-helical conformation and exert inhibitory effects on the kinase activity of Kit 71 .
As such, deletions/mutations/insertions that disrupt this conformation would all be expected to result in constitutive activation of Kit.
Indolinone compounds inhibit the growth of mast cell lines expressing mutant Kit through cell cycle arrest and apoptosis
To identify a receptor tyrosine kinase (RTK) inhibitor capable of blocking the function of all forms of mutant Kit, we investigated the effects of three indolinones that act as competitive inhibitors with respect to ATP at the intracellular catalytic domain of the receptor 59,60,72-76 .
These indolinones, denoted SU11652, SU11654, and SU11655 (SUGEN, Inc.), inhibit several members of the split kinase family of RTKs including VEGFR, FGFR, PDGFR and Kit (Fig. 2 , Table 1 ). The core structure of these indolinones is predicted to bind to Kit in a similar fashion as observed in the SU5402/SU6668 co-crystal structure with FGFR1. The functional group off the pyrrole ring extends to the opening of the ATP binding site, which is hydrophilic and exposed to solvent 73 . This is in contrast to the crystal structure of an STI571 analog in Abl where the inhibitor protrudes to the hydrophobic end of the ATP binding site by pushing up the flexible activation loop 77 . To determine if these compounds were capable of disrupting various forms of mutant Kit, we utilized the cell lines described above, each of which possesses a unique mutation in c-kit leading to constitutive phosphorylation in the absence of SCF stimulation.
To assess the effects of the indolinones on cell proliferation, BR, C2 or P815 cells were cultured with SU11652, SU11654, or SU11655 at a variety of concentrations and the number of remaining cells was determined at 24, 48, and 72 hours of culture. Interestingly, the two cell lines expressing Kit JM mutations (BR and C2) required lower concentrations of indolinones for inhibition of cell proliferation than did the cell line expressing a catalytic domain mutation (P815) (Fig. 3) . Both of these cell lines demonstrated growth inhibition at concentrations as low as 0.01 µM. However, the effect of indolinone treatment was more profound on the P815 line as no live cells were noted after 24 hours of culture at 0.5 µM (Fig. 3) . The cell line expressing WT Kit (C57) is a growth factor independent mast cell line and could not be assessed in this model, as additional genomic mutations render it relatively resistant to the effects of these indolinones.
As such, inhibition of cell proliferation was only noted at very high indolinone concentrations (10 µM) (data not shown).
In the cell survival assays detailed above, we observed not only a decrease in absolute cell numbers, but also morphologic features consistent with apoptosis. To distinguish between cell cycle arrest and cell death, we evaluated the cells by propidium iodide staining after treatment with SU11652, SU11654, or SU11655. Cells were treated with various concentrations of drug for 24, 48, or 72 hours, then collected for flow cytometric analysis. The cell line expressing the catalytic domain mutation (P815) exhibited rapid apoptosis within 24 hours at concentrations between 0.25-0.5 µM. Cell cycle arrest was not noted prior to apoptosis, and apoptosis did not occur at concentrations less than 0.25 µM (Fig. 4) . Instead, cell cycle arrest was the principle effect of drug treatment on this cell line. Similar to the previous experiment, the effects of the three indolinones on cell cycling and apoptosis were not evaluated in C57 cells as this growth factor independent mast cell line expresses additional genomic mutations that render it relatively resistant to the effects of these compounds.
To more specifically evaluate the timing of apoptosis after indolinone treatment, we Ideally, an effective RTK inhibitor would exhibit good oral bioavailability, a large volume of distribution, an elimination half-life that permits daily dosing, and the ability to block the function of a restricted set of proteins. We chose to investigate the potential utility of three multi-targeted indolinones in the inhibition of dysfunctional Kit signaling, as these compounds possess a number of such desirable features.
We utilized four mast cell lines expressing either WT Kit or a variety of Kit mutants to investigate the ability of three indolinones (denoted SU11652, SU11654, and SU11655) to disrupt Kit function. These compounds were effective in blocking cell proliferation in all cell lines expressing mutant Kit (Fig 3) . For those lines expressing a JM Kit mutation, treatment with (Fig. 6 ). Both JM mutants were also inhibited by SU11652, SU11654, and SU11655 with a similar IC 50 (Fig. 6) . Interestingly, the catalytic domain mutant required a higher concentration of drug for maximal inhibition, with an IC 50 of 0.25-0.5 µM (Fig 6) . This is in agreement with a prior study examining an earlier indolinone (SU6577) in which higher concentrations of drug were necessary to block the catalytic domain mutant when compared to a JM domain mutant 78 . Differences in levels of protein are unlikely to be responsible for this discrepancy, as cell surface expression of Kit is comparable among the various mutants (Fig. 1) .
Given that activating mutations in the catalytic domain of Kit induce significant PI3-kinase activity and are potent inducers of malignant transformation, it is possible that this form of mutation may result in greater constitutive activation of Kit when compared to the JM mutations.
In conclusion, our data demonstrate that, in contrast to other tyrosine kinase inhibitors, the multi-targeted indolinones SU11652, SU11654, and SU11655 are potent inhibitors of both WT and mutant forms of Kit at concentrations of drug that are readily achievable in vivo (Table   2) For
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